Hoxb4 upregulation by Xuan Bi Tong Yu Fang confers cardioprotection via repression of the Wnt/β-catenin pathway in myocardial ischemia-reperfusion injury - Summary - MDSpire
Advertisement
Hoxb4 upregulation by Xuan Bi Tong Yu Fang confers cardioprotection via repression of the Wnt/β-catenin pathway in myocardial ischemia-reperfusion injury
To investigate the cardioprotective mechanisms of Xuan Bi Tong Yu Fang (XBTYF) in myocardial ischemia-reperfusion injury (MIRI).
Key Findings:
XBTYF significantly reduced myocardial enzyme levels and infarct size in the MIRI model.
Histopathological analysis showed improved myocardial architecture and reduced fibrosis.
RNA sequencing identified Hoxb4 as a key gene upregulated by XBTYF, with a notable inhibition of the Wnt/β-catenin pathway.
Molecular docking revealed strong binding of ginsenoside Rg3 to Hoxb4.
In vitro, XBTYF increased Hoxb4 levels, promoting cell proliferation and reducing apoptosis.
Interpretation:
XBTYF exerts cardioprotective effects in MIRI by enhancing Hoxb4 expression and inhibiting the Wnt/β-catenin signaling pathway, leading to reduced apoptosis in cardiomyocytes.
Limitations:
The study was conducted in a rodent model, which may not fully replicate human responses.
Long-term effects and potential side effects of XBTYF were not evaluated.
Conclusion:
XBTYF shows promise as an adjunctive therapy for myocardial ischemia-reperfusion injury by modulating Hoxb4 and the Wnt/β-catenin pathway, warranting further clinical investigation.
Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients
Revised American Heart Association statement urges a shift toward plant-based protein and flags ongoing uncertainty in fat and alcohol recommendations.
